KalVista Pharmaceuticals achieves key goals in late-stage study for hereditary angioedema therapy, demonstrating significant efficacy of sebetralstat. FDA approval filing ...
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Vertex Pharmaceuticals is capturing the attention of investors with its expansion into pain management and cell/gene therapies. With positive earnings ...
FDA approves Takeda's EOHILIA as first-line treatment for Eosinophilic Esophagitis. Groundbreaking oral therapy offers hope for improved quality of life.